Whitehawk Therapeutics (NASDAQ:WHWK) Research Coverage Started at Jones Trading

Jones Trading initiated coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

WHWK has been the subject of a number of other reports. Zacks Research raised Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Whitehawk Therapeutics in a report on Monday, December 15th. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics to a “strong sell” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Whitehawk Therapeutics has a consensus rating of “Hold” and a consensus target price of $7.00.

Whitehawk Therapeutics Trading Up 1.5%

Shares of WHWK opened at $2.69 on Monday. The company has a market cap of $126.78 million, a P/E ratio of 19.21 and a beta of 0.38. The company has a 50-day moving average price of $2.33. Whitehawk Therapeutics has a one year low of $1.39 and a one year high of $3.81.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.25. Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 68.32%.

Institutional Investors Weigh In On Whitehawk Therapeutics

A number of institutional investors have recently modified their holdings of WHWK. Orbimed Advisors LLC acquired a new position in shares of Whitehawk Therapeutics in the third quarter valued at about $7,915,000. Suvretta Capital Management LLC acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth approximately $7,030,000. Acuta Capital Partners LLC bought a new position in shares of Whitehawk Therapeutics during the third quarter worth approximately $6,480,000. Avoro Capital Advisors LLC bought a new position in shares of Whitehawk Therapeutics during the third quarter worth approximately $5,414,000. Finally, Yu Fan acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at approximately $3,933,000. Institutional investors own 52.08% of the company’s stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.